



CORPORATE PRESENTATION

ONLINE STORE COMING JANUARY 2022

CSE: PILL | OTCQB: CTABF | FSE:TBF1

DISCLAIMER



This presentation contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", or "will be taken", "occur", or "be achieved". Forward-looking information is based on the opinions and estimates of management at the date the information is made, and is based on a number of assumptions and is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including risks related to market and financing conditions as well as risks associated with the industries in which the Company operates, changes in project parameters as plans continue to be refined as well as other risk factors. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information contained herein.

WHAT WE DO



We are the **leading innovator of cannabinoid and terpene blends in hard pill form** for therapeutic applications.

- **Online store launching in January 2022!**
- **Three patents granted in the United States, Canada, and Australia.**
- **Seven pending patent applications internationally.**
- **Sales license granted by Health Canada (November 9th, 2021)**

Canntab believes its unique hard pill formulations are superior to all other medical CBD and THC delivery systems that provide superior ingredient stability, enhanced bioavailability, customizable and precise dosing.

STRONG IP PORTFOLIO



3 patents granted, with 7 more patents pending in the United States and Canada covering our **proprietary processes** and **hard pill formulations** for,

- **Extended Release**
- **Sustained Release**
- **Immediate Release** (CA and AU Patent Granted)
- **Modified-Release Multi-Layer** (US Patent Granted)
- **Flash-Melt / Oral Dissolvable Tablet**
- **Bi-Layered**



In August 2019, the Geneva-based International Preliminary Report on Patentability (“IPRP”) indicated a positive finding of patentability for our **Instant Release** Cannabidiol formulation, meaning that, in their opinion, Canntab’s formulation is not only **patentable** but also **novel, non-obvious** and **useful**.

INTELLECTUAL PROPERTY CREATES VALUE FOR SHAREHOLDERS

PROPRIETARY PROCESS

Our patent pending proprietary processes allows us to create hard pill formulations that starts with the highest quality cannabis oil in water emulsions, a unique process in the industry to date.

Oil emulsion >> wet granulation >> dried granulation >> blending >> tablet pressing >> coating



**OUR INNOVATIVE PROCESS CREATES A HARD PILL THAT MEETS MEDICAL STANDARDS,
AND FOLLOWS PHARMACEUTICAL MANUFACTURING GUIDELINES.**

MEETING MEDICAL STANDARDS

Current delivery mechanisms such as smoking or vaping cannabis, consuming edibles, gel caps, oils and tincture (droppers) do not provide the medical community, including Doctors, patients or the average consumer, with an attractive and professional cannabis solution.


	CANNTAB Hard Pills	Flower	Oils	Gel Capsules	Edibles
Uniform Dosage	✓	✗	✗	✗	✗
Extended Release Option	✓	✗	✗	✗	✗
Safe Delivery	✓	✗	✗	✓	✗
Discreet	✓	✗	✗	✓	✓
Shelf Life	✓	✗	✗	✗	✗
Bioavailability	●	◐	◑	◐	◑

THERAPEUTIC WINDOW

Smoking cannabis can result in a large initial dose of the drug followed by a precipitous drop.

Edibles dosing is unpredictable, making it difficult to maintain therapeutic relief.

Our solution, an extended release (XR) tablets with flash melt technology, quickly brings the patient into the **therapeutic window** and maintains that dosage.



CANNTAB'S XR HARD PILL SOLUTION KEEPS PATIENTS IN THE THERAPEUTIC WINDOW, MAINTAINING SYMPTOM RELIEF WHILE AVOIDING NEGATIVE SIDE EFFECTS.

HOW WE GENERATE REVENUE



As of March 15th 2021, we've manufactured almost two million hard pills at our Markham Ontario facility. These hard pills are for our partners, including **MediPharm (Toronto)** and **Cann Global (Australia)**, and for our online store coming out in January 2022.

Our revenue streams include,



ONLINE STORE
SALES Q1 2022



LICENSING OUR
TECHNOLOGY



EXPORT SALES



WHITE LABEL

TABLET ECONOMICS



Illustrative Gross Margin Sensitivity Analysis

100K Customers Worldwide, 2 pills/day	Low	Base	High
Gross Margin per Pill	\$0.50	\$0.75	\$1.00
Annual Margin per Customer	<u>\$365</u>	<u>\$548</u>	<u>\$730</u>
Annual Gross Margin	\$36.5 MM	\$54.8 MM	\$73 MM
100K Customers Worldwide, 3 pills/day	Low	Base	High
Gross Margin per Pill	\$0.50	\$0.75	\$1.00
Annual Margin per Customer	<u>\$547</u>	<u>\$821</u>	<u>\$1095</u>
Annual Gross Margin	\$ 54.7MM	\$82.1 MM	\$109.5 MM

Note: Sensitivity Analysis is meant to be illustrative and is not intended to be used as a forecast.

CAPITALIZATION



Shares Outstanding	37,334,937
Stock Options	3,002,926
Special Warrants	2,450,000
Broker Warrants	401,480
Common Share Purchase Warrants*	7,655,750
*from march 2020 unit offering	
Fully Diluted Total Shares Outstanding	51,045,093

1-YEAR CHART



52 Week Range **0.5700 - 1.0900**

Market Cap **25.006M**

As of market close,
December 10th, 2021

MANAGEMENT TEAM



Richard Goldstein, Co-Founder *Chief Financial Officer*

- Founder First Republic Capital, Co-Founder Fraser McKenzie, former EVP/Head of IB at Standard Securities.
- 28 years of capital markets experience.
- MBA in Finance from McMaster University.

Larry Latowsky *Chief Executive Officer*

- Former President and CEO of Drug Trading.
- Former President and CEO of Katz Group Canada.
- Canntab intends to appoint Larry Latowsky as a Director and Executive Chairman of the Board.

Laxaminarayan Joshi *Chief Science Officer*

- Over 20 years of experience in pharmaceuticals.
- Previously was Director of R&D for Orbus Pharma Inc.
- An expert in the formulation of cannabinoids.

SUMMARY



- **January 2022 release of our new online platform and online store, to include a telehealth department that will facilitate registration and customer care throughout the purchase process.**
- Full scale **hard pill manufacturing has begun** at our facility in Markham, Ontario.
- We received a **US Patent No. 10772837** for “Modified Release Multi-Layer Tablet Cannabinoid Formulations” indicating that our formulations are patentable.
- We received a **Canadian Patent No. CA 3050150** for “Immediate Release Cannabinoid Tablets.”
- We received a **Australian Patent No. AU 2018210690** further solidifying our protection for Immediate Release Tablets in the Australian market, coinciding with an Australian deal with our partner Cann Global.

LOOKING AT THE FUTURE



➤ **ONLINE STORE OPENS JANUARY 2022.**

- **Blood level studies in Canada and Australia** will be conducted in 2022, as the first steps towards further clinical trials designed to advance our understanding of Canntab's unique formulations.
- **Partnering with an MSO in the United States**, or internationally, to further our reach around the world, leveraging our patented, proprietary processes.
- **Clinical trial with Dr. Garbuz at UBC** to investigate potentially opioid sparing CBD/THC formulations in 2021, as we work towards acquiring Drug Identification Numbers (DINs).
- Additional clinical trials using our patent pending delivery mechanism and formulation capabilities for **Sleep, Pain, Arthritis, Irritable Bowel Syndrome, and Tempomandibular Joint Disorder** to follow in 2022.

CONTACT US



Richard Goldstein

Co-founder & Chief Financial Officer

(647) 209-3279

Richard@Canntab.ca

Larry Latowsky

Chief Executive Officer

(416) 458-6491

Larry@Canntab.ca

Frank Candido

Business Development Consultant

(514) 969-5530

Frank@Canntab.ca